AYGEN, B. Et Al. 2019. Adverse effects of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin therapy in patients with hepatitis C virus genotype 1/4 infection: Real-life experience in Turkey. 28th Annual Conference Acian Pacific Association for the Study of the Liver .

AYGEN, B., DEMİRTÜRK, N., YILDIZ, O., ÇELEN, M. K., ÇELİK, İ., BARUT, H. Ş., ... URAL, O.(2019). Adverse effects of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin therapy in patients with hepatitis C virus genotype 1/4 infection: Real-life experience in Turkey . 28th Annual Conference Acian Pacific Association for the Study of the Liver

AYGEN, BİLGEHAN Et Al. "Adverse effects of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin therapy in patients with hepatitis C virus genotype 1/4 infection: Real-life experience in Turkey," 28th Annual Conference Acian Pacific Association for the Study of the Liver, 2019

AYGEN, BİLGEHAN Et Al. "Adverse effects of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin therapy in patients with hepatitis C virus genotype 1/4 infection: Real-life experience in Turkey." 28th Annual Conference Acian Pacific Association for the Study of the Liver , 2019

AYGEN, B. Et Al. (2019) . "Adverse effects of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin therapy in patients with hepatitis C virus genotype 1/4 infection: Real-life experience in Turkey." 28th Annual Conference Acian Pacific Association for the Study of the Liver .

@conferencepaper{conferencepaper, author={BİLGEHAN AYGEN Et Al. }, title={Adverse effects of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin therapy in patients with hepatitis C virus genotype 1/4 infection: Real-life experience in Turkey}, congress name={28th Annual Conference Acian Pacific Association for the Study of the Liver}, city={}, country={}, year={2019}}